Combined DMT-harmine formulation reduces negative self-referential emotions during social self-evaluation: a randomized placebo-controlled trial in healthy volunteers.

Saved in:
Bibliographic Details
Title: Combined DMT-harmine formulation reduces negative self-referential emotions during social self-evaluation: a randomized placebo-controlled trial in healthy volunteers.
Authors: Aicher HD; Psychedelic Research & Therapy Development, Department of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Lenggstrasse 31, P.O. Box 363, CH-8032, Zurich, Switzerland. helena.aicher@uzh.ch.; Department of Psychology, University of Zurich, Zurich, Switzerland. helena.aicher@uzh.ch.; Experimental Pharmacopsychology and Psychological Addiction Research, Department of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland. helena.aicher@uzh.ch., Dornbierer J; Psychedelic Research & Therapy Development, Department of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Lenggstrasse 31, P.O. Box 363, CH-8032, Zurich, Switzerland. joellealine.dornbierer@uzh.ch.; Neuroscience Center Zurich (ZNZ), University of Zurich and ETH Zurich, Zurich, Switzerland. joellealine.dornbierer@uzh.ch., Caflisch L; Psychedelic Research & Therapy Development, Department of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Lenggstrasse 31, P.O. Box 363, CH-8032, Zurich, Switzerland.; Department of Psychology, University of Zurich, Zurich, Switzerland., Suay D; Psychedelic Research & Therapy Development, Department of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Lenggstrasse 31, P.O. Box 363, CH-8032, Zurich, Switzerland.; MoMiLab, IMT School for Advanced Studies, Lucca, Italy., Mueller MJ; Psychedelic Research & Therapy Development, Department of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Lenggstrasse 31, P.O. Box 363, CH-8032, Zurich, Switzerland., Landolt HP; Neuroscience Center Zurich (ZNZ), University of Zurich and ETH Zurich, Zurich, Switzerland.; Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland., Quednow BB; Experimental Pharmacopsychology and Psychological Addiction Research, Department of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland.; Neuroscience Center Zurich (ZNZ), University of Zurich and ETH Zurich, Zurich, Switzerland., Scheidegger M; Psychedelic Research & Therapy Development, Department of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Lenggstrasse 31, P.O. Box 363, CH-8032, Zurich, Switzerland., Dornbierer D; Psychedelic Research & Therapy Development, Department of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Lenggstrasse 31, P.O. Box 363, CH-8032, Zurich, Switzerland.
Source: Psychopharmacology [Psychopharmacology (Berl)] 2026 Jul 14. Date of Electronic Publication: 2026 Jul 14.
Publication Type: Journal Article
Journal Info: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7608025 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2072 (Electronic) Linking ISSN: 00333158 NLM ISO Abbreviation: Psychopharmacology (Berl) Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1432-2072
DOI:10.1007/s00213-026-07118-4